Abstract
A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer. Metformins anti-breast cancer actions, observed in population studies, in rodents and in cultured tumour cells, are especially encouraging because they attack not only the most common bulk of the tumour cells but also the more rare tumour-initiating stem cells. Here, we illustrate the multifaceted and redundant mechanisms through which metformin-reprogrammed energy metabolism at both the organismal and cellular levels constitutes a novel and valuable strategy to prevent and treat breast cancer disease.
Keywords: Insulin, Diabetes, Metformin, Breast cancer, AMPK, Stem cells, Carcinogenesis, Hyperinsulinaemia, Biguanide derivative, Inflammation, Oestrogen, Apoptosis, IGF, Tumouricidal effect, Neoplasias, Adenocarcinomas, Thiazolidinediones, Sulfonylureas, Glibenclamide, Chemotherapy, Gluconeogenesis, Insulinaemia, Aerobic glycolysis, Oxidative phosphorylation, Mitosis, Glucose tolerance, Aromatase expression, Tyrosine kinase inhibitors, Antibodies, Supplementation, Lapatinib, Trastuzumab, Anti-HER2 therapy, PARP inhibitors, EGFR, Anti-cancer drugs, Cytotoxics, Anthracycline doxorubicin
Current Molecular Medicine
Title: Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Volume: 10 Issue: 7
Author(s): A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cufi, B. Martin-Castillo and J. A. Menendez
Affiliation:
Keywords: Insulin, Diabetes, Metformin, Breast cancer, AMPK, Stem cells, Carcinogenesis, Hyperinsulinaemia, Biguanide derivative, Inflammation, Oestrogen, Apoptosis, IGF, Tumouricidal effect, Neoplasias, Adenocarcinomas, Thiazolidinediones, Sulfonylureas, Glibenclamide, Chemotherapy, Gluconeogenesis, Insulinaemia, Aerobic glycolysis, Oxidative phosphorylation, Mitosis, Glucose tolerance, Aromatase expression, Tyrosine kinase inhibitors, Antibodies, Supplementation, Lapatinib, Trastuzumab, Anti-HER2 therapy, PARP inhibitors, EGFR, Anti-cancer drugs, Cytotoxics, Anthracycline doxorubicin
Abstract: A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer. Metformins anti-breast cancer actions, observed in population studies, in rodents and in cultured tumour cells, are especially encouraging because they attack not only the most common bulk of the tumour cells but also the more rare tumour-initiating stem cells. Here, we illustrate the multifaceted and redundant mechanisms through which metformin-reprogrammed energy metabolism at both the organismal and cellular levels constitutes a novel and valuable strategy to prevent and treat breast cancer disease.
Export Options
About this article
Cite this article as:
Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Martin-Castillo B. and A. Menendez J., Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells, Current Molecular Medicine 2010; 10 (7) . https://dx.doi.org/10.2174/156652410792630625
DOI https://dx.doi.org/10.2174/156652410792630625 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Editorial (Thematic Issue: The Crosstalk between Non-Pharmaceutical and Pharmaceutical Approaches to Prevention and Treatment of Chronic Diseases: Current Concepts and Perspectives)
Current Pharmaceutical Design DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Editorial (Thematic Issue: Signal Transduction, Targeted Therapy and Cancer: From Bench to Clinics)
Current Pharmaceutical Design Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel
Anti-Cancer Agents in Medicinal Chemistry Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Current Treatment Concepts of CML
Current Cancer Drug Targets Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders CPP-Based Bioactive Drug Delivery to Penetrate the Blood-Brain Barrier: A Potential Therapy for Glioblastoma Multiforme
Current Drug Targets Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Inflammasome, Inflammation and Cancer: An Interrelated Pathobiological Triad
Current Drug Targets Real-time Monitoring of Nanoparticle-based Therapeutics: A Review
Current Drug Metabolism The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and Related Compounds
Current Medicinal Chemistry